Trading Update

Smith & Nephew Plc 20 June 2003 20 June 2003 Smith & Nephew Close Period Trading Update Smith & Nephew plc, the advanced medical devices group, has continued to achieve strong double-digit sales growth during the first half of 2003 in its largest and fastest-growing business - Orthopaedics. Overall underlying sales growth for Smith & Nephew in the first half of 2003 is expected to be around 10%. Acquisitions will add 1% to this growth, but currency will be 3% adverse. Orthopaedics will lead the group with underlying sales growth of around 15% as anticipated, with continued strong reconstructive growth of 19% and trauma growth of 10%. Wound Management's underlying growth is running at 7%, a slower than expected start, largely due to delays in production expansion in the US. Sales of Dermagraft are on track and we expect Wound Management to return to previous growth levels in the second half. As previously indicated, we anticipate Endoscopy's sales growth will slow to 5%, mainly due to increased blade reuse in the US, but is expected to improve for the full year with a number of new product launches in the second half. Sir Christopher O'Donnell, Chief Executive of Smith & Nephew said, 'We are pleased with the growth of our orthopaedics business and believe increased sales of new products will accelerate our overall sales growth in the second half of the year. We remain on track to meet our full-year financial targets.' Smith & Nephew is to give a briefing to investors and analysts today ahead of the close period, which precedes its interim results announcement. The briefing will be via conference call at 3 pm UK time, and can be heard by live audio webcast via the Smith & Nephew website at www.smith-nephew.com. A recording of the briefing will be available on the Smith & Nephew website after the call. Smith & Nephew, whose business is focused on the fast growing markets for orthopaedics, endoscopy and advanced wound management products, will report interim results on 31 July. Enquiries: Smith & Nephew Angie Craig Tel: +44 (0)20 7401 7646 Corporate Affairs Director Financial Dynamics David Yates Tel: +44 (0)20 7831 3113 This information is provided by RNS The company news service from the London Stock Exchange
UK 100